EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Standard form for notification of major holdings 

Further announcement regarding the exclusive license and collaboration agreement with Icahn School of Medicine at Mount Sinai in New York, USA.

Renalytix AI plc to develop Artificial Intelligence solutions for early identification and management of kidney disease

8th May 2018

EKF Diagnostics confirms that the Annual Report and Accounts for the year ended 31 December 2017, the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website

EKF announces US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the Company’s hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm, approving the product for use in point of care and Certificate of Waiver settings.

Standard form for notification of major holdings 

14th Mar 2018

EKF Diagnostics Holdings announces its final results for the year ended 31 December 2017.

EKF Diagnostics Holdings announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.

11th Jan 2018

EKF Diagnostics Holdings plc provides shareholders with the following update on current trading.